GordonMD and EPIQ Capital led a $115m Series B round in SalioGen Therapeutics.

GordonMD, an investment company, and EPIQ Capital, a private equity firm, led a $115m Series B round in SalioGen Therapeutics, a biotechnology firm. “We are grateful to have support from a world-class group of committed investors. This investment will support our research and development efforts and accelerate the company’s ability to position multiple therapeutic programs for clinical development. Grounded by a shared mission to transform the treatment paradigm for patients with inherited diseases, the team and advisory boards we’ve built have unparalleled expertise to usher in the first applications of Gene Coding,” Ray Tabibiazar, SalioGen Chief Executive Officer and Chairman.